In a randomized, placebo-controlled trial, 30,000 IU per week was given for 24 weeks to prevent worsening of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in women starting letrozole therapy for breast cancer [35]. This evidence concerns the gene CYP19A1 and breast carcinoma.